ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Treatment of Active Chronic Antibody-Mediated Rejection with Rituximab, IVIG and Plasma Exchange

G. Piñeiro,1 J. Rovira,2 E. De Sousa-Amorim,1 J. Villarreal,1 M. Sole,3 I. Revuelta,1 M. Lozano,4 E. Palou,4 F. Oppenheimer,1 J. Campistol,1 F. Diekmann.1,2

1Nephrology and Renal Transplantation, Hospital Clinic de Barcelona, Barcelona, Spain
2Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
3Pathology, Hospital Clinic de Barcelona, Barcelona, Spain
4Apheresis Unit, Hemotherapy and Hemostasis, Hospital Clinic de Barcelona, Barcelona, Spain
5Immunology, Hospital Clinic de Barcelona, Barcelona, Spain.

Meeting: 2018 American Transplant Congress

Abstract number: 209

Keywords: Antibodies, Graft survival, Kidney transplantation, Rejection

Session Information

Date: Monday, June 4, 2018

Session Name: Concurrent Session: Kidney Chronic Antibody Mediated Rejection

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:30pm-3:42pm

Location: Room 4B

Related Abstracts
  • Chronic Active Antibody Mediated Rejection (cABMR): Treatment, Outcomes and Predictors of Graft Loss in a Large Case Series
  • Tocilizumab as Treatment for Persistent Chronic Active Antibody Mediated Rejection.

Chronic antibody-mediated rejection (cABMR) and transplant glomerulopathy (TG) are main features associated with long-term graft loss. Despite its clinical significance, the available evidence on treatment of cABMR and TG is scarce.

Methods/Materials. 63 patients with TG (cg≥1) and active cABMR diagnosis (Microvascular injury (g+ptc≥2), between 2006 and 2015 were analyzed retrospectively. 24 patients were treated with Rituximab (RTX) in combination with IVIG and plasma exchange and one only with RTX; the others 39 were not treated or only intensified maintenance immunosuppression. The efficacy and safety of the therapy were analyzed.

Results: Treated patients were younger (43 vs. 53 yrs., p 0.01). Charlson comorbidity index (CCI) was lower in treated patients, but not statistically different. Time on dialysis prior to transplant, glomerular filtrate rate and proteinuria at diagnosis of cABMR were similar in both groups. Acute inflammatory and chronic lesions related to cABMR and TG were similar in both groups (Banff 2013). Only C4d deposition was more frequent in treated patients (p<0.001).

The mean dose of RTX was 985.9±351mg and 79.2% receive two doses. RTX treatment began from 1 to 3 weeks after cABMR diagnosis. Graft survival censoring death was equal in both groups (Log Rank 0.74). At 24 months, 9 and 13 patients lost their grafts in RTX and control, respectively (p=0.68). Glomerular filtrate rate deterioration was similar in both groups. Infections requiring hospitalization within one year after treatment were more frequent in RTX patients, 0.62 vs. 0.25 infections/patients (OR=3.9, p=0.017). A CCI of 3 was associated with higher incidence of infections in the untreated group (p=0.036), but not in the treated patients (p=0.14).

RTX therapy, alone or in combination with IVIG and PE, was not effective in treatment of active cABMR with TG and was associated with an important increase in serious infectious complications.

CITATION INFORMATION: Piñeiro G., Rovira J., De Sousa-Amorim E., Villarreal J., Sole M., Revuelta I., Lozano M., Palou E., Oppenheimer F., Campistol J., Diekmann F. Treatment of Active Chronic Antibody-Mediated Rejection with Rituximab, IVIG and Plasma Exchange Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Piñeiro G, Rovira J, Sousa-Amorim EDe, Villarreal J, Sole M, Revuelta I, Lozano M, Palou E, Oppenheimer F, Campistol J, Diekmann F. Treatment of Active Chronic Antibody-Mediated Rejection with Rituximab, IVIG and Plasma Exchange [abstract]. https://atcmeetingabstracts.com/abstract/treatment-of-active-chronic-antibody-mediated-rejection-with-rituximab-ivig-and-plasma-exchange/. Accessed February 25, 2021.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.